Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA

HIV Medicine

Volumn 14, Issue 10, 2013, Pages 614-623

  Grint, D ^a   Peters, L ^b   Schwarze Zander, C ^c   Beniowski, M ^d   Pradier, C ^e   Battegay, M ^f   Jevtovic, D ^g   Soriano, V ^h   Lundgren, J D ^b   Rockstroh, J K ^c   Kirk, O ^b,i   Mocroft, A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF BONN   (Germany)

^d Specialised Hospital   (Poland)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g UNIVERSITY OF BELGRADE   (Serbia)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ University of Copenhagen   (Denmark)

Author keywords

EuroSIDA; HIV HCV coinfection; PEG interferon; Ribavirin; Treatment completion

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; EUROPE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; PRIORITY JOURNAL; TREATMENT DURATION;

EUROSIDA; HIV/HCV COINFECTION; PEG-INTERFERON; RIBAVIRIN; TREATMENT COMPLETION;

ADULT; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COINFECTION; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; RIBAVIRIN;

EID: 84885469418     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12068     Document Type: Article

References (36)

1. Gill J, May M, Lewden C etal. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-1396.
2. Mocroft A, Reiss P, Gasiorowski J etal. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. Jaids-J Acquir Immune Defic Syndr 2010; 55: 262-270.
3. Weber R, Sabin CA, Friis-Moller N etal. Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study. Arch Intern Med 2006; 166: 1632-1641.
4. Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus - a 20-year prospective study. Jaids-J Acquir Immune Defic Syndr 2008; 47: 221-225.
5. Graham CS, Baden LR, Yu E etal. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-569.
6. Rockstroh JK, Bhagani S, Benhamou Y etal. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9: 82-88.
7. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
8. Opravil M, Sasadeusz J, Cooper DA etal. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008; 47: 36-49.
9. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36: 97-100.
10. Fultz SL, Justice AC, Butt AA, Rabeneck L, Weissman S, Rodriguez-Barradas M. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis 2003; 36: 1039-1046.
11. Mocroft A, Rockstroh J, Soriano V etal. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scand J Infect Dis 2006; 38: 1092-1097.
12. Rauch A, Egger M, Reichen J, Furrer H. Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin. Jaids-J Acquir Immune Defic Syndr 2005; 38: 238-240.
13. Mocroft A, Ledergerber B, Katlama C etal. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
14. Grint D, Peters L, Reekie J etal. Stability of hepatitis C virus (HCV) RNA levels among interferon-na+»ve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Med 2013; n/a.
15. Soriano V, Mocroft A, Rockstroh J etal. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008; 198: 1337-1344.
16. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-847.
17. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-293.
18. Peters L, Mocroft A, Soriano V etal. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients. Plos One 2013; 8: e64283.
19. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. Aids 2008; 22: 1979-1991.
20. Wai CT, Greenson JK, Fontana RJ etal. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
21. Peters L, Rockstroh JK. Biomarkers of fibrosis and impaired liver function in chronic hepatitis C: how well do they predict clinical outcomes? Curr opin HIV AIDS 2010; 5: 517-523.
22. Resino S, Bellon J, Asensio C etal. Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients? BMC Infect Dis 2010; 10: 244.
23. Resino S, S+ínchez-Conde M, Berenguer J. Coinfection by human immunodeficiency virus and hepatitis C virus: noninvasive assessment and staging of fibrosis. Curr Opin Infect Dis 2012; 25: 564-569.
24. Beste LA, Ioannou GN, Larson MS, Chapko M, Dominitz JA. Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clin Gastroenterol Hepatol 2010; 8: 972-978.
25. Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol 2012; 56: 320-325.
26. Effect of hepatitis C treatment on CD4+ T-cell counts and the risk of death in HIV-HCV-coinfected patients: the COHERE collaboration. Antivir Ther 2012; 17: 1541-1550.
27. Carrat F. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA (Chicago, Ill) 2004; 292: 2839-2848.
28. Chung RT, Andersen J, Volberding P etal. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-459.
29. Laguno M. Randomized trial comparing pegylated interferon α-2b versus pegylated interferon α-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009; 49: 22-31.
30. Ingiliz P. HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver Int 2012; 32: 1194-1199.
31. Naggie S. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012; 142: 1324-1334.
32. Thompson AJ, Muir AJ, Sulkowski MS etal. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-U178.
33. Rauch A, Martin M, Weber R etal. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV cohort study. Clin Infect Dis 2005; 41: 395-402.
34. van de Laar TJ, van der Bij AK, Prins M etal. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007; 196: 230-238.
35. Deterding K. Early versus delayed treatment of acute hepatitis C: final results of the randomized controlled German hep-net acute HCV-III study. J Hepatol 2012; 56: S21.
36. Gerlach JT. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-88.